ChemPartner PharmaTech Co Ltd
ChemPartner PharmaTech Co Ltd provides drug discovery and development services to pharmaceutical and biotechnology companies, primarily through contract research and development agreements.
Business. ChemPartner PharmaTech Co Ltd (300149.SZ) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in China and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ChemPartner PharmaTech Co Ltd (300149.SZ) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in China and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
ChemPartner maintains a debt-to-equity ratio of 0.37, indicating a relatively conservative capital structure with equity significantly outweighing liabilities. The company's liquidity position is assessed as medium, with operating cash flow of 190,498,810 CNY and capital expenditures of -62,469,660 CNY, suggesting moderate cash flow generation and reinvestment. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.
Profitability metrics for ChemPartner are not explicitly provided, but the company's operating cash flow suggests a positive cash-generating business model. The company's debt-to-equity ratio is below the industry median for Biotechnology & Medical Research firms, indicating a lower financial leverage risk compared to peers.
ChemPartner's revenue is not segmented by geographic region or product line in the available data, but the company operates primarily in the healthcare diagnostics and drug discovery services space. Given the nature of the industry, the company likely serves a global client base, though specific geographic exposure is not disclosed.
The company's growth trajectory is not explicitly quantified in the input data, but the current revenue of 1,134,719,480 CNY and the operating cash flow suggest a stable business model. The capital expenditure of -62,469,660 CNY indicates ongoing investment in infrastructure or operations, which may support future growth.
Risk factors for ChemPartner include a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could limit its ability to fund operations or expansion without external financing. No dilution risk is flagged in the data, and no adjustments to valuation metrics are reported.
Recent events or filings are not detailed in the input data, but the company's financial snapshot and valuation metrics suggest a stable, cash-flow positive business with moderate leverage. The absence of recent dilutive events or significant regulatory changes implies a relatively stable operating environment.
- ChemPartner maintains a conservative capital structure with a debt-to-equity ratio of 0.37.
- The company generates positive operating cash flow, indicating a cash-flow positive business model.
- ChemPartner's liquidity is assessed as medium, with a negative net cash position after subtracting total debt.
- The company's growth trajectory is not explicitly quantified, but ongoing capital expenditures suggest investment in future growth.
- The company faces low dilution risk and no significant adjustments to valuation metrics are reported.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- ChemPartner PharmaTech Co Ltd Market data — financials · 2026-05-26
Ownership & reference
Leadership
- Xianwei ZengChairman of the Board, Chief Executive Officer